Merck KGaA’s antibody-drug conjugate (ADC), precemtabart tocentecan, has shown to be safe and tolerable in a Phase Ib trial.

Merck KGaA (OTC:MKGAF) is seeking worldwide regulatory approval for its CSF-1R inhibitor pimicotinib following robust Phase ...

Merck KGaA is filing for global regulatory approvals of pimicotinib after it met primary and secondary endpoints in a Phase ...

Merck KGaA has shown off data that fueled its $85 million bet on a late-phase treatment for a rare, locally aggressive tumor.

By Ludwig Burger FRANKFURT (Reuters) -German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more ...

The global Biomarkers Market, valued at US$58.07 billion in 2024 stood at US$62.39 billion in 2025 and is projected to ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the broader biopharma industry. | Citing tariff threats, Merck KGaA has ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Shares fell after the company cut its full-year guidance on the back of challenging macroeconomic conditions and ...

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want ...

NEW YORK/FRANKFURT, April 28 (Reuters) - (This April 28 story has been corrected to clarify the deal's regulatory status in Europe, in paragraph 11) Sign up here. The deal came at a price tag ...